Evidence Snapshot

Adrenergic receptor alpha-2

CHEMBL2095158 PROTEIN FAMILY Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T18:48:15Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 3:48 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2095158

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Adrenergic receptor alpha-2 as ChEMBL target CHEMBL2095158, mapped to UniProt P08913. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Adrenergic receptor alpha-2

PROTEIN FAMILY · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2095158

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P08913

Alpha-2A adrenergic receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Adrenergic receptor alpha-2 matters

As of 2026-09-13

Adrenergic receptor alpha-2 is reviewed as Alpha-2A adrenergic receptor (UniProt P08913); Adrenergic receptor alpha-2 shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 29 approved drugs, 495 compounds, and 230 assays, with lead potency reaching pChEMBL 10.8.

Protein context

Alpha-2A adrenergic receptor

Alpha-2A adrenergic receptor Sequence length is 465 aa.

Review this target as Adrenergic receptor alpha-2, mapped to UniProt P08913. ChEMBL maps the protein component as Alpha-2A adrenergic receptor. Sequence length is 465 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P08913 Protein

Disease context

hypertension

Adrenergic receptor alpha-2 shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BRIMONIDINE TARTRATE, CLONIDINE, CLONIDINE HYDROCHLORIDE.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include BRIMONIDINE TARTRATE, CLONIDINE, CLONIDINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 5 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 29 approved drugs, 495 compounds, and 230 assays for this target. The dominant activity type is KI. CHEMBL553231 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL553231 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine

29 approved pChEMBL 10.8

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Adrenergic receptor alpha-2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08913, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hypertension is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

495

Total Compounds

230

Total Assays

Approved Drugs

IC50: 77.0, KI: 340.0, EC50: 82.0, KD: 50.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL553231	10.8	IC50	—
No preferred name CHEMBL557985	10.8	IC50	—
No preferred name CHEMBL537830	10.5	IC50	—
No preferred name CHEMBL10347	10.0	Ki	—
No preferred name CHEMBL538801	9.9	IC50	—